Innovative laboratory techniques shaping cancer diagnosis and treatment in developing countries

Discover Oncology, Год журнала: 2025, Номер 16(1)

Опубликована: Фев. 8, 2025

Abstract Cancer is a major global health challenge, with approximately 19.3 million new cases and 10 deaths estimated by 2020. Laboratory advancements in cancer detection have transformed diagnostic capabilities, particularly through the use of biomarkers that play crucial roles risk assessment, therapy selection, disease monitoring. Tumor histology, single-cell technology, flow cytometry, molecular imaging, liquid biopsy, immunoassays, diagnostics emerged as pivotal tools for detection. The integration artificial intelligence, deep learning convolutional neural networks, has enhanced accuracy data analysis capabilities. However, developing countries face significant challenges including financial constraints, inadequate healthcare infrastructure, limited access to advanced technologies. impact COVID-19 further complicated management resource-limited settings. Future research should focus on precision medicine early diagnosis sophisticated laboratory techniques improve prognosis outcomes. This review examines evolving landscape detection, focusing breakthroughs limitations countries, while providing recommendations advancing tumor resource-constrained environments.

Язык: Английский

---

Ochratoxin A and Its Role in Cancer Development: A Comprehensive Review

Cancers, Год журнала: 2024, Номер 16(20), С. 3473 - 3473

Опубликована: Окт. 14, 2024

Ochratoxin A (OTA) is widely recognized for its broad spectrum of toxic effects and classified as a potential human carcinogen, placed in group 2B by the International Agency Research on Cancer (IARC). Its presence food beverages poses significant health hazard. Extensive research has documented efficient absorption distribution OTA throughout body via bloodstream tissues, underscoring associated risk. Additionally, ongoing studies aim to clarify link between exposure carcinogenesis. The obtained results indicate strong correlation renal cell carcinoma (RCC), with associations other malignancies, including hepatocellular (HCC), gallbladder cancer (GBC), squamous (SCC). implicated oxidative stress, lipid peroxidation, apoptosis, DNA damage, adduct formation, miRNA deregulation, distributions cycle, all which may contribute

Язык: Английский

---

Comparing loss of contractual employment pre- and post-diagnosis in patients with rare versus common cancer types: a national registry-based study

Journal of Cancer Survivorship, Год журнала: 2025, Номер unknown

Опубликована: Янв. 6, 2025

Язык: Английский

---

Revolutionizing Oncology: Iron Oxide Nanoparticles in Cancer Diagnosis and Treatment

International Journal of Scientific Research in Science and Technology, Год журнала: 2025, Номер 12(1), С. 161 - 173

Опубликована: Янв. 26, 2025

Iron oxide nanoparticles (IONPs) have emerged as a transformative tool in oncology, offering unprecedented opportunities for early cancer diagnosis and effective treatment. These exhibit unique physicochemical properties, including superparamagnetism, biocompatibility, large surface area-to-volume ratio. properties make them particularly suitable applications such high-resolution imaging, targeted drug delivery, hyperthermia therapy. Additionally, their ability to be functionalized with various biomolecules enables precision targeting of cancerous tissues, further enhancing efficacy. This article delves into the cutting-edge advancements utilization IONPs, examines multifunctional roles addresses challenges clinical translation, outlines future directions research application this dynamic field.

Язык: Английский

---

Understanding Diagnostic Costs Using Hospital-Based Encounters in the Year Before Diagnosis for Canadian Patients with Malignant Central Nervous System Tumours Compared to Common Cancers

Current Oncology, Год журнала: 2025, Номер 32(2), С. 96 - 96

Опубликована: Фев. 9, 2025

Rare cancers pose significant diagnostic challenges, leading to more tests and higher healthcare expenditures (HEs). Understanding the financial implications of diagnosing rare is crucial, particularly in Canada, where overall HEs are high (12% GDP 2023). We investigated pre-diagnostic hospital-based HE for patients with malignant central nervous system (CNS) tumours compared it common across Canadian provinces, using in-patient ambulatory care data (2010-2014) from Institute Health Information. Pre-diagnostic was calculated as change total (in-patient out-patient) during 12 months before diagnosis, within this period minus average annual estimated over two preceding years. Comparison groups included pediatric diagnosed leukemia aged 15 colorectal cancer lung cancer. used quantile regression estimate adjusted effect diagnosis a CNS tumour on HE. The results indicated that those cancers. top three factors contributing variation were encounter type (in-patient/out-patient), province (Alberta/Ontario), comorbidities (yes/no). Further investigation warranted understand drivers cost differences.

Язык: Английский

---

Designing Clinical Trials for Patients With Rare Cancers: Connecting the Zebras

American Society of Clinical Oncology Educational Book, Год журнала: 2025, Номер 45(3)

Опубликована: Апрель 14, 2025

The field of rare cancer research is rapidly transforming, marked by significant progress in clinical trials and treatment strategies. Rare cancers, as defined the National Cancer Institute, occur fewer than 150 cases per million people each year, yet they collectively represent a portion all diagnoses. Because their infrequency, these cancers pose distinct challenges for trials, including limited patient populations, geographical dispersion, general lack awareness options. Economic limitations further complicate drug development, making initiatives such Orphan Drug Act essential incentivizing research. advent next-generation sequencing (NGS) precision medicine has been instrumental identifying actionable genetic alterations parallel with an explosion development genomically targeted therapies, immunotherapies, antibody conjugates. Advances NGS, medicine, tumor-agnostic therapies have become central to approval drugs, BRAF, NTRK, RET inhibitors, immunotherapy mismatch repair deficient/microsatellite instability–high status highlight potential personalized treatments across diverse types age spectrum. Collaborative from cooperative groups SWOG DART, ASCO TAPUR, NCI-MATCH, pediatric COG-match, DRUP, IMPRESS, innovative registrational basket platform (eg, VE-Basket, ROAR, LIBRETTO-001, ARROW), along advocacy group-run like TRACK, are enhancing access trials. In addition, artificial intelligence improve trial matching process. An integrated approach, combining innovations collaboration multiple stakeholders, crucial advancing research, offering hope better outcomes quality life.

Язык: Английский

---

Preclinical 3D model screening reveals digoxin as an effective therapy for a rare and aggressive type of endometrial cancer

Gynecologic Oncology, Год журнала: 2024, Номер 188, С. 162 - 168

Опубликована: Июль 5, 2024

Язык: Английский

---

A comprehensive review on the current status of CRISPR based clinical trials for rare diseases

International Journal of Biological Macromolecules, Год журнала: 2024, Номер 277, С. 134097 - 134097

Опубликована: Июль 25, 2024

Язык: Английский

---

Commentary on ‘Mutation detection in saliva from oral cancer patients’

Oral Oncology, Год журнала: 2024, Номер 156, С. 106937 - 106937

Опубликована: Июль 4, 2024

Язык: Английский

---